Results 1 to 10 of about 131,732 (302)

Reverse transcriptase inhibitors diminish systemic proinflammatory responses to bacterial pathogens [PDF]

mBio
Bacterial infections can induce exuberant immune responses that can damage host tissues. Previously, we demonstrated that systemic Escherichia coli infection in mice causes tissue damage in the liver. This liver necrosis is associated with the expression
Karthik Hullahalli, Katherine G. Dailey, Ryan Acbay, Masataka Suzuki, George I. Balazs, Matthew K. Waldor   +5 more
doaj   +2 more sources

In silico prediction of telomerase reverse transcriptase inhibitors using modified retinol for the treatment of arsenical cancer [PDF]

Bangabandhu Sheikh Mujib Medical University Journal, 2016
Retinol molecule was modified to predict the inhibitors of telomerase reverse transcriptase for the treatment of arsenical cancer through in silico study. Telomerase activity is expressed in the cancerous conditions which can be the target for anticancer
Kipchu Tshering, Mir Misbahuddin
doaj   +3 more sources

Approved HIV reverse transcriptase inhibitors in the past decade [PDF]

Acta Pharmaceutica Sinica B, 2022
HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.
Guangdi Li, Yali Wang, Erik De Clercq
doaj   +2 more sources

HTLV-1 reverse transcriptase homology model provides structural basis for sensitivity to existing nucleoside/nucleotide reverse transcriptase inhibitors [PDF]

Virology Journal
The human T-lymphotropic virus type 1 (HTLV-1) infects millions of people globally and is endemic to various resource-limited regions. Infections persist for life and are associated with increased susceptibility to opportunistic infections and severe ...
Nicolas Tardiota, Noushin Jaberolansar, Julia A. Lackenby, Keith J. Chappell, Jake S. O’Donnell   +4 more
doaj   +2 more sources

Proposal of pharmacophore model for HIV reverse transcriptase inhibitors: Combined mutational effect analysis, molecular dynamics, molecular docking and pharmacophore modeling study [PDF]

International Journal of Immunopathology and Pharmacology
Objectives: Antiretroviral therapy (ART) efficacy is jeopardized by the emergence of drug resistance mutations in HIV, compromising treatment effectiveness.
Azzeddine Annan, Noureddine Raiss, Sanae Lemrabet, Nezha Elomari, El Harti Elmir, Abdelkarim Filali-Maltouf, Leila Medraoui, Hicham Oumzil   +7 more
doaj   +2 more sources

Cost-effectiveness of the third-agent class in treatment-naive human immunodeficiency virus-infected patients in Portugal. [PDF]

PLoS ONE, 2012
IntroductionCurrent Portuguese HIV treatment guidelines recommend initiating antiretroviral therapy with a regimen composed of two Nucleoside Reverse Transcriptase Inhibitors plus one Non-nucleoside Reverse Transcriptase Inhibitor (2NRTI+NNRTI) or two ...
Filipa Aragão, José Vera, Inês Vaz Pinto   +2 more
doaj   +1 more source

Capacity of rTth polymerase to detect RNA in the presence of various inhibitors. [PDF]

PLoS ONE, 2018
The full potential of the real-time reverse transcription polymerase chain reaction (RT-PCR) as a rapid and accurate diagnostic method is limited by DNA polymerase inhibitors as well as reverse transcriptase inhibitors which are ubiquitous in clinical ...
Dongyang Cai, Ole Behrmann, Frank Hufert, Gregory Dame, Gerald Urban   +4 more
doaj   +1 more source

Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. [PDF]

PLoS Pathogens, 2006
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) target HIV-1 reverse transcriptase (RT) by binding to a pocket in RT that is close to, but distinct, from the DNA polymerase active site and prevent the synthesis of viral cDNA.
Anna Figueiredo, Katie L Moore, Johnson Mak, Nicolas Sluis-Cremer, Marie-Pierre de Bethune, Gilda Tachedjian   +5 more
doaj   +1 more source

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study

Frontiers in Microbiology, 2022
Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons
Prince Kofi Parbie, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Dennis Kushitor, Theodore Worlanyo Asigbee, Theodore Worlanyo Asigbee, Nana Afia Asante Ntim, Nana Afia Asante Ntim, Gifty Addo-Tetebo, Maclean Richard Darko Ansong, Sampson Badu Ofori, Taketoshi Mizutani, Lucky Ronald Runtuwene, Masako Nishizawa, Koichi Ishikawa, Hiroshi Kiyono, Hiroshi Kiyono, Hiroshi Kiyono, William Kwabena Ampofo, Tetsuro Matano, Tetsuro Matano, Tetsuro Matano, Evelyn Yayra Bonney, Tadashi Kikuchi   +24 more
doaj   +1 more source

Drogas anti-VIH: passado, presente e perspectivas futuras Drugs anti-HIV: past, present and future perspectives

Química Nova, 2003
Currently available anti-HIV drugs can be classified into three categories: nucleoside analogue reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).
Marcus Vinícius Nora de Souza, Mauro Vieira de Almeida   +1 more
doaj   +1 more source